As your expert extension, Evestia Clinical offers specialized support for the unique challenges of rare disease clinical trials.
We understand the critical need for tailored approaches in this sensitive area and are committed to working alongside biotech companies to bring meaningful therapies to patients.
Our experienced teams possess a deep understanding of rare disease nuances, including patient identification and retention, often working with patient advocacy groups to enhance trial success.
We prioritize a partnership approach, becoming a seamless part of your team to navigate the complexities of each trial phase with agility and dedication. Recognizing the importance of continuity, we strive to provide stable, dedicated teams with accessible leadership.
Our commitment extends to incorporating a strong patient-centric perspective, exemplified by our active development of a rare disease forum/patient advocacy group to provide valuable insights and ensure the patient voice is central to our strategies.
Our experience spans both adult and pediatric rare disease trials, with over 120 studies collectively informing our approach. Today, 50% of our team has direct rare disease expertise, bringing valuable insight into the operational and emotional complexities of these programs.
Our collective track record includes work across a diverse range of conditions — such as ALS, hemophilia, Tuberous Sclerosis Complex, Primary Mitochondrial Myopathy, lupus, sickle cell disease, and multiple rare tumor types. This depth of experience enables us to adapt quickly to your program’s needs while always keeping the patient journey at the heart of our strategies.
